India Drug Industry Urged To Look Away From U.S. To CIS Nations
This article was originally published in PharmAsia News
Executive Summary
India's pharmaceutical industry is expected to suffer more than any other sector under the new U.S. presidency of Barack Obama, according to Promed Group President Deepak Bahri. The group makes and markets branded and generic drugs globally. Bahri said the new administration is likely to clamp down on outsourcing to the Indian market and allow greater generics competition to Indian drugs in the United States. He also advised drug makers to focus more on the former Soviet countries that have formed the Commonwealth of Independent States, a group making major changes in old health care systems. (Click here for more
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.